Shanghai Biopharmaleader co.,ltd

If you are going to consult the information about 1009119-64-5 from one of the leading 1009119-64-5 manufacturers and suppliers in China,Website:://.biopharmaleader.net, Biopharmaleader Co.,Ltd is always at your service.Product InformationCAS NO.1009119-64-5 Product NameDaclatasvirSynonymsBMS-790052FormulaC40H50N8O6Molecular Weight738.88Spec / Purity98%minSupply CapacityDetailsDaclatasvir is a drug for the treatment of hepatitis C (HCV). It was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.